Third Rock Ventures led the funding round, which also included financing from Clal Biotechnology Industries and Access Industries. Neon Therapeutics was founded by experts in neoantigen biology, tumor
In 2005, Merck bought the rights to Kuvan and Peg-Pal, another PKU treatment, outside the US and Japan. BioMarin will pay Merck €340m for Kuvan and about €185m
Under the deal, Ferring will pay Apricus $2.25m and about $16m in regulatory and sales milestone payments, apart from royalties depending on the product’s net sales. Ferring will
The move marks first product opt-in since the companies formed an alliance in January last year to speed up and expand the development and commercialization of RNAi therapeutics
The company said the variant is for the patients not taking chronic inhaled aminoglycoside antibiotics. If approved, Translarna would be the first oral protein restoration treatment that targets
In addition, GSK sold its marketed oncology portfolio to Novartis India. The transaction follows a worldwide transaction between their parent firms GSK and Novartis, which was completed earlier
APP-111 showed efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer. In preclinical studies, the drug appeared to have less peripheral
Under a collaboration and option agreement signed in June 2012, Liquidia was entitled to receive an upfront payment including cash and equity, R&D funding, and possible development milestones
The company has already started first of the facility expansions at various locations in Germany including its Ravensburg Vetter West center for visual inspection and logistics. Vetter completed
In July last year, the EC granted orphan designation for beloranib to treat Prader-Willi syndrome (PWS). Beloranib is being studied as a first-in-class obesity therapy that shows a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.